QUIT-LIKE-SWEDEN
29.5.2024 14:22:31 CEST | Business Wire | Press release
Millions of lives could be saved with a more progressive approach to tobacco control measures, says a new platform committed to encouraging countries to follow the Swedish Experience and become ‘smoke-free’. As the world gears up to observe World No Tobacco Day (WNTD) on May 31, Quit Like Sweden, launched earlier this year in Brazil, is calling for proven strategies to enhance the global fight against smoking.
Traditionally, WNTD has been marked exclusively by calls for the complete abandonment of smoking. However, Quit Like Sweden argues that it's time for policymakers, regulators, governments, the media, and the general public to engage in a meaningful discussion about the strategies that do reduce the devastating impacts of smoking and smoking-related illnesses.
Suely Castro, Founder of Quit Like Sweden, emphasized the need for a new approach, citing the Swedish Experience and remarkable progress in tobacco control.
"Each World No Tobacco Day, the international community argues that a world without cigarettes is the ultimate aim. But this World No Tobacco Day, instead of discussing what could be possible, it’s time to look at what is already being done by the only country that is close to quitting smoking: Sweden," said Suely Castro.
While Sweden has rigorously adopted smoking cessation and prevention measures, it has also enabled smokers to choose safer alternatives. This approach, based on what Ms Castro calls the three A's – which stand for the Accessibility, Acceptability, and Affordability of safer alternatives – has resulted in millions of Swedes choosing to leave cigarettes behind and switch to safer alternatives.
"In Sweden, one in four adults uses nicotine every day. While this is the same level as the rest of Europe, Sweden’s incidence of cancer is 41% lower, and smoking-related deaths in Sweden are less than half of smoking-related deaths in 24 of the other 26 EU countries”, Castro said.
“This is the case within European countries, which have similar regulations to those of Sweden, although not its comprehensive approach to eradicating smoking. Just imagine what the global impact of the full Swedish Experience could be.”
“We have the ability to save millions of lives just by replicating a model that has already worked so well for Sweden,” she said. "And there’s no better time to start that conversation than now.”
Background
Quit Like Sweden is a not-for-profit platform with the aim to encourage countries to take action to replicate the Swedish Experience in a comprehensive strategy that also includes measures and programmes focused on smoking cessation and prevention, and enabling people who smoke to choose alternatives instead.
We don’t advocate for the removal of measures and programmes that contribute to smoking cessation or prevention, and instead appeal to all policymakers in all countries, intergovernmental and non-governmental organizations to complement those measures and programmes.
Sweden Statistics
As a result of Sweden’s progressive tobacco control measures:
- Sweden is the only country in the world to officially be ‘smoke-free’, when its smoking prevalence falls below 5% later this year.
- Across Europe, the smoking rate is 5 times higher than Sweden’s.
- 24 of the 27 EU countries have a tobacco-related mortality rate at least twice as high as Sweden’s.
- Sweden’s incidence of cancer is 41% lower than the rest of Europe’s, which means 38% lower levels of total cancer deaths.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529797728/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
